The role of radiotherapy for early stage Hodgkin's disease: Limitations and perspectives

Annals of Oncology

Volumn 9, Issue SUPPL. 5, 1998, Pages

  Cosset, J M ^a   Mauch, P M ^b  

^a INSTITUT CURIE   (France)

^b HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

Author keywords

Chemotherapy; Chemotherapy radiotherapy combination; Hodgkin's disease; Limited stages; Radiotherapy

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; HODGKIN DISEASE; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; RADIATION CARCINOGENESIS; RADIATION DOSE; RADIATION INJURY; SECOND CANCER; TREATMENT PLANNING;

EID: 0032448384     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/9.suppl_5.S57     Document Type: Conference Paper

References (19)

1. Gilbert R, Babaiantz L. Noire méthode de rocntgentherapie de la lymphogranulomatose (Hodgkin): Résultats éloignés. Acta Radiol 1931; 12: 523-9.
2. Gilbert R. Radiotherapy in Hodgkin's disease (malignant granulomatosis): Anatomic and clinical foundations: Governing principles, results. Am J Roentgenol 1939; 41: 198-241.
3. Peters M. A study in survivals in Hodgkin's disease treated radiologically. Am J Roentgenol 1950; 63: 299-311.
4. Peters M, Middlemiss K. A study of Hodgkin's disease treated by irradiation. Am J Roentgenol 1958; 79: 114-21.
5. Kaplan H. Hodgkin's Disease. Cambridge: Harvard University Press 1980.
6. Tubiana M, Henry-Amar.M, Carde P et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 1989; 73: 47-56.
7. Cosset J, Ferme C, Noordijk E et al. Combined modality therapy for poor prognosis stages I and II Hodgkin's disease. Semin Radiat Oncol 1996; 6: 185-95.
8. Jones E, Mauch P. Limited radiation therapy for selected patients with stages IA and IIA Hodgkin's disease. Semin Radiat Oncol 1996; 6: 162-71.
9. Mauch P, Tarbell N, Weinstein H et al. Stage IA and IIA supradiaphragmatic Hodgkin's disease: Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 1988; 6: 1576-83.
10. Mauch P. Controversies in the management of patients with early stage Hodgkin's disease. Blood 1994; 83: 318-29.
11. Leibenhaut M, Hoppe R, Efron B et al. Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. J Clin Oncol 1989; 7: 81-91.
12. Mauch P, Larson D, Osteen R et al. Prognostic factors for positive surgical staging in patients with Hodgkin's disease. J Clin Oncol 1990; 8: 257-65.
13. Specht L. Prognostic factors in Hodgkin's disease. Semin Radial Oncol 1996; 6: 146-61.
14. Carde P, Hagenbeek A, Hayat M et al. Clinical staging versus laparotomy and combined modality with MOPP remis ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11: 2258-72.
15. Noordijk E, Carde P, Hagenbeek A et al. Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin's disease. Six-year results of the EORTC-GPMC controlled clinical trials 'H7-VF', 'H7-F'and 'H7-U'. Int J Radiat Oncol Biol Phys 1997; 39: 173 (Abstr).
16. Noordijk E, Carde P, Mandard A et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early stage Hodgkin's disease. Ann Oncol 1994; 5: 107-12.
17. Hancock S, Hoppe R. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 1996; 6: 225-42.
18. Cosset J, Henry-Amar M, Meerwaldt J. Long-term toxicity of early stages of Hodgkin's disease therapy: The EORTC experience. Ann Oncol 1991; 2: 77-82.
19. Mauch P, Kalish L, Marcus K et al. Long-term survival in Hodgkin's disease: Relative impact of mortality, infection, second tumors, and cardiovascular disease. Cancer J Sci Am 1995; 1: 33-42.